Nasdaq: PODDInsulet Corporation

    Insulet Q3 2026 Results: Net Income $141 Million on Revenue of $842 Million

    • US stocks
    • Earnings
    • Health Care

    Insulet (Nasdaq: PODD) reported third-quarter 2026 results for the quarter ended 30 Sep 2026, with GAAP revenue of $842.0 million and GAAP net income of $141.1 million, it said on 4 Nov 2026. Diluted EPS on a GAAP basis was $2.03, and adjusted EPS, a company-defined measure that excludes a warranty cost adjustment and a debt extinguishment loss, was $1.99.

    Key highlights

    • Revenue (GAAP): $842.0 million, up 19.2% YoY and 5.0% QoQ
    • Net income (GAAP): $141.1 million, up 61.1% YoY and 48.5% QoQ
    • Diluted EPS (GAAP): $2.03, up 63.7% YoY
    • Adjusted EPS (company-defined): $1.99, against $1.24 a year earlier
    • Operating margin (GAAP): 22.5%, up 5.8 percentage points YoY

    Summary

    Consolidated (GAAP) $ million
    ParticularsQ3 2026Q3 2025YoYQ2 2026QoQ
    Revenue842.0706.3+19.2%801.7+5.0%
    189.8117.7+61.3%129.7+46.3%
    141.187.6+61.1%95.0+48.5%
    Diluted EPS ($)2.031.24+63.7%1.37+48.2%

    Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.

    Revenue rose 19.2% from the third quarter of 2025, to $842.0 million from $706.3 million. Operating income rose 61.3% to $189.8 million, and the GAAP operating margin was 22.5%, against 16.7% a year earlier. Net income rose 61.1% to $141.1 million from $87.6 million.

    Against the second quarter of 2026, revenue rose 5.0%, operating income rose 46.3% and net income rose 48.5%, to $141.1 million from $95.0 million. GAAP diluted EPS was $2.03, against $1.37 in the previous quarter.

    Adjusted figures exclude a warranty cost adjustment

    Adjusted operating income was $185.2 million, or 22.0% of revenue, on the company's own measure. The release says the adjustments include a $4.5 million net warranty and related cost adjustment linked to the voluntary medical device corrections issued in March and May 2026, and a $0.3 million loss on debt extinguishment that it ties to the repricing of its Term Loan B.

    Adjusted net income was $138.0 million, up 57.2% from $87.8 million, and adjusted diluted EPS rose 59.9% from $1.24. The company also gives adjusted EBITDA of $233.7 million for the quarter, a company-defined measure, against $160.0 million a year earlier.

    Omnipod revenue grew in both regions

    U.S. Omnipod revenue was $570.4 million, up 14.7%. International Omnipod revenue was $266.2 million, up 31.7%, or 33.0% in constant currency. Drug Delivery revenue was $5.5 million, against $7.1 million a year earlier.

    The company said that for the nine months operating cash flow was $325.7 million, against $386.0 million a year earlier, and that free cash flow, a company-defined measure, was $211.7 million, against $329.5 million. Capital expenditures were $113.9 million in the same nine months.

    Full-year 2026 outlook raised for revenue and margin

    The company now expects total revenue growth of 21% to 22% at constant currency, up from 20% to 22%, and adjusted operating margin expansion of about 150 basis points, up from about 100 basis points. It keeps its outlook for adjusted EPS growth of more than 30%. Its GAAP revenue growth outlook for 2026 is 22% to 23%.

    Inference

    Weighted-average diluted shares were 69.5 million in the quarter, against 70.7 million a year earlier. The company said its board signed off on a $1 billion buyback, and that roughly $400 million of it is planned for the fourth quarter of 2026, paid from cash on hand.

    The release does not say how much of the $1 billion program will remain after those fourth quarter purchases, and it does not state a dividend. The next dated step it gives is the planned fourth quarter 2026 repurchases.

    Filed with the US SEC on . Reference: Original filing (SEC)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

    Latest posts